Helicobacter pylori Infection - Associated Intestinal Metaplasia: A Comparative, Controlled, Longitudinal Clinical Study on the Efficacy of Hyperbaric Ozone Autohemotherapy
Gastric intestinal metaplasia is a precancerous lesion frequently associated with chronic H.pylori infection, representing a key stage in the gastric carcinogenesis cascade. Although bacterial eradication reduces the risk of progression to gastric adenocarcinoma, the efficacy of standard treatment in reversing intestinal metaplasia remains limited, particularly in extensive or incomplete forms. In this context, hyperbaric ozone autohemotherapy (AHT-O₃) is proposed as a therapeutic adjuvant with antioxidant, anti-inflammatory and immunomodulatory potential. This comparative, controlled and longitudinal clinical study evaluated the efficacy of AHT-O₃ combined with conventional therapy in 60 adult patients diagnosed with intestinal metaplasia and active H.pylori infection. The AHT-O₃-treated group showed a significant reduction in malondialdehyde (MDA) levels and an increase in the activity of antioxidant enzymes (SOD, GPx, GST), compared to the control group (p less than 0.001). Additionally, a stimulation of T-helper lymphocytes and a decrease in pro-inflammatory lymphocytes were observed, indicating a robust immunoregulatory effect. The H.pylori eradication rate was higher in the ozone group (84% vs. 60%, p = 0.04), with a significantly greater decrease in IgA and IgG titers (p less than 0.01). Endoscopic and histological evaluation after 12 months showed an increased rate of complete and partial regression of intestinal metaplasia lesions and a marked reduction in gastric mucosal inflammation. The GIQLI score indicated a significant improvement in quality of life in the ozone-treated group. These results support the inclusion of AHT-O₃ as a viable complementary option in the therapeutic strategy for H.pylori-associated intestinal metaplasia, with a positive impact on the clinical, biochemical, and histological progression of the condition.